Analysis of Significantly Different Bacteria. by Xu Jia (187142)

Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

Analysis of Significantly Different ARGs and Resistance Mechanisms. by Xu Jia (187142)

AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. by Xiaoqin Li (1399105)

Map of Zimbabwe highlighting the districts detected as persistent hotspots of <i>S. haematobium</i> prevalence (PPHS), persistent hotspots of decreased praziquantel efficacy (EPHS)... by Takafira Mduluza (39754)

Box plots showing baseline prevalence and mean egg count at pre-MDA1 in districts that were responders compared to those that were persistent hotspots of decreasing praziquantel ef... by Takafira Mduluza (39754)

S2 File - Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Va... by Sonsawan Sangprasert (22772538)

Detailed treatment status of people who received non- pharmacological treatment at first diagnosis. by Mingee Choi (15250732)

Subjects:

Distribution of continuous variables of all 3 visits of group 1 (placebo) and group 2 (placebo) that have no significant difference among the groups. by Nattapon Riengvirodkij (11268720)

Subjects:

Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Treatment at first diagnosis of insomnia disorder (%). by Mingee Choi (15250732)

Subjects:

Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later. by Mingee Choi (15250732)

Subjects:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Variation of the most appropriate p value significance threshold with different ratios of the standard deviations and sample sizes. by Farrokh Habibzadeh (12256529)

Baseline descriptive characteristics of trial participants with dizziness, by treatment group. by Anneli Peolsson (7867601)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”